This site is intended for health professionals only!

Early data released from Phase IIIb Cimzia trial

teaser

Six-week data from the WELCOME trial presented at the third congress of the European Crohn’s and Colitis Organisation (ECCO) show Cimzia® (certolizumab pegol), the first and only PEGylated anti-TNF-alpha, to be effective in Crohn’s patients who are intolerant, or are no longer responding to infliximab.

This is the first presentation of the initial six-week induction results from WELCOME, a 539-patient, Phase IIIb multicentre study of the effects of Cimzia on Crohn’s patients for whom infliximab treatment was not successful.

During this six-week induction stage, all patients received 400mg of Cimzia subcutaneous at Weeks 0, 2 and 4.  At Week 6, 61 percent of the patients had achieved the primary endpoint of response, defined as a decrease in Crohn’s Disease Activity Index (CDAI)* score >=100 points from baseline. In addition, 39 percent of the patients were in remission, defined as a CDAI score <=150 points.

“These induction results are very promising,” commented study investigator Professor Severine Vermeire of Katholieke Universiteit Leuven, Belgium. “The WELCOME data show that certolizumab pegol could be a treatment option for patients with Crohn’s disease who are refractory to other biological agents, showing consistent results across all patient groups.”

In the WELCOME study, Cimzia has demonstrated a low incidence of injection site pain (less than 2%). The most commonly occurring AEs were headache, nasopharyngitis, nausea, vomiting, pyrexia and arthralgia. The incidence of serious adverse events (SAEs) was 7% and the most frequent SAEs involved gastrointestinal disorders (5%) and infections and infestations (2%).

In September 2007, Cimzia, manufactured by Belgium-based biopharma firm UCB, was approved in Switzerland for the treatment of Crohn’s disease and it was launched in January 2008.

UCB Group



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: